244 related articles for article (PubMed ID: 32304896)
1. Moderate and severe exacerbations have a significant impact on health-related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis.
Guo J; Chen Y; Zhang W; Tong S; Dong J
Int J Surg; 2020 Jun; 78():28-35. PubMed ID: 32304896
[TBL] [Abstract][Full Text] [Related]
2. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease.
Solem CT; Sun SX; Sudharshan L; Macahilig C; Katyal M; Gao X
Int J Chron Obstruct Pulmon Dis; 2013; 8():641-52. PubMed ID: 24376348
[TBL] [Abstract][Full Text] [Related]
3. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.
Martin AL; Marvel J; Fahrbach K; Cadarette SM; Wilcox TK; Donohue JF
Respir Res; 2016 Apr; 17():40. PubMed ID: 27084761
[TBL] [Abstract][Full Text] [Related]
4. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV
Chai CS; Ng DL; Bt Mos S; Ibrahim MAB; Tan SB; Pang YK; Liam CK
BMC Pulm Med; 2023 Apr; 23(1):150. PubMed ID: 37118725
[TBL] [Abstract][Full Text] [Related]
5. Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data.
Stöber A; Lutter JI; Schwarzkopf L; Kirsch F; Schramm A; Vogelmeier CF; Leidl R
Int J Chron Obstruct Pulmon Dis; 2021; 16():2637-2651. PubMed ID: 34588773
[TBL] [Abstract][Full Text] [Related]
6. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
Ni H; Htet A; Moe S
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011897. PubMed ID: 28631387
[TBL] [Abstract][Full Text] [Related]
7. Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
Dreyse J; Díaz O; Repetto PB; Morales A; Saldías F; Lisboa C
Int J Chron Obstruct Pulmon Dis; 2015; 10():525-33. PubMed ID: 25792820
[TBL] [Abstract][Full Text] [Related]
8. Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial.
Jackson D; Jenkins M; de Nigris E; Purkayastha D; Patel M; Ouwens M
Qual Life Res; 2024 Apr; 33(4):1029-1039. PubMed ID: 38206455
[TBL] [Abstract][Full Text] [Related]
9. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study.
Miravitlles M; Ferrer M; Pont A; Zalacain R; Alvarez-Sala JL; Masa F; Verea H; Murio C; Ros F; Vidal R;
Thorax; 2004 May; 59(5):387-95. PubMed ID: 15115864
[TBL] [Abstract][Full Text] [Related]
10. Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis.
Jordan RE; Majothi S; Heneghan NR; Blissett DB; Riley RD; Sitch AJ; Price MJ; Bates EJ; Turner AM; Bayliss S; Moore D; Singh S; Adab P; Fitzmaurice DA; Jowett S; Jolly K
Health Technol Assess; 2015 May; 19(36):1-516. PubMed ID: 25980984
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
12. Impact of mild exacerbation on COPD symptoms in a Japanese cohort.
Sato M; Chubachi S; Sasaki M; Haraguchi M; Kameyama N; Tsutsumi A; Takahashi S; Nakamura H; Asano K; Betsuyaku T
Int J Chron Obstruct Pulmon Dis; 2016; 11():1269-78. PubMed ID: 27354785
[TBL] [Abstract][Full Text] [Related]
13. Unreported and Overlooked: A Post Hoc Analysis of COPD Symptom-Related Attacks from the RISE Study.
Ferguson GT; Skärby T; Nordenmark LH; Lamarca R; Aksomaityte A; Lythgoe D; Gilbert I; Trudo F
Int J Chron Obstruct Pulmon Dis; 2020; 15():3123-3134. PubMed ID: 33273814
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life of patients diagnosed with COPD in Extremadura, Spain: results from an observational study.
Merino M; Villoro R; Hidalgo-Vega Á; Carmona C;
Health Qual Life Outcomes; 2019 Dec; 17(1):189. PubMed ID: 31888646
[TBL] [Abstract][Full Text] [Related]
15. Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.
Exuzides A; Colby C; Briggs AH; Lomas DA; Rutten-van Mölken MPMH; Tabberer M; Chambers M; Muellerova H; Locantore N; Risebrough NA; Ismaila AS; Gonzalez-McQuire S
Med Decis Making; 2017 May; 37(4):453-468. PubMed ID: 26449490
[TBL] [Abstract][Full Text] [Related]
16. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
[TBL] [Abstract][Full Text] [Related]
17. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
18. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
Seemungal TA; Donaldson GC; Paul EA; Bestall JC; Jeffries DJ; Wedzicha JA
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1418-22. PubMed ID: 9603117
[TBL] [Abstract][Full Text] [Related]
19. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
20. Impact of COPD exacerbations leading to hospitalization on general and disease-specific quality of life.
Camac ER; Voelker H; Criner GJ;
Respir Med; 2021 Sep; 186():106526. PubMed ID: 34229290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
